US Food and Drug Administration Approvals of Drugs and Devices Based on Nonrandomized Clinical Trials: A Systematic Review and Meta-analysis by Razavi, Marianne et al.
Bond University
Research Repository
US Food and Drug Administration Approvals of Drugs and Devices Based on Nonrandomized
Clinical Trials
Razavi, Marianne; Glasziou, Paul; Klocksieben, Farina A; Ioannidis, John P A; Chalmers, Iain;
Djulbegovic, Benjamin
Published in:
JAMA network open
DOI:
10.1001/jamanetworkopen.2019.11111
10.1001/jamanetworkopen.2019.11111
Published: 04/09/2019
Document Version:
Publisher's PDF, also known as Version of record
Link to publication in Bond University research repository.
Recommended citation(APA):
Razavi, M., Glasziou, P., Klocksieben, F. A., Ioannidis, J. P. A., Chalmers, I., & Djulbegovic, B. (2019). US Food
and Drug Administration Approvals of Drugs and Devices Based on Nonrandomized Clinical Trials: A Systematic
Review and Meta-analysis. JAMA network open, 2(9), [1911111].
https://doi.org/10.1001/jamanetworkopen.2019.11111, https://doi.org/10.1001/jamanetworkopen.2019.11111
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
For more information, or if you believe that this document breaches copyright, please contact the Bond University research repository
coordinator.
Download date: 06 Nov 2019
Original Investigation | Statistics and ResearchMethods
US Food and Drug Administration Approvals of Drugs and Devices
Based on Nonrandomized Clinical Trials
A Systematic Review andMeta-analysis
Marianne Razavi, PhD; Paul Glasziou, MD, PhD; Farina A. Klocksieben, MS; John P. A. Ioannidis, MD, DSC; Iain Chalmers, MD; Benjamin Djulbegovic, MD, PhD
Abstract
IMPORTANCE The size of estimated treatment effects on the basis of which the US Food and Drug
Administration (FDA) has approved drugs and devices with data from nonrandomized clinical trials
(non-RCTs) remains unknown.
OBJECTIVES To determine how often the FDA has authorized novel interventions based on
non-RCTs and to assess whether there is an association of themagnitude of treatment effects with
FDA requirements for additional testing in randomized clinical trials (RCTs).
DATA SOURCES Overall, 606 drug applications for the Breakthrough Therapy designation from its
inception in January 2012 were downloaded from the FDAwebsite in January 2017 and August 2018,
and 71medical device applications for the Humanitarian Device Exemption from its inception in June
1996were downloaded in August 2017.
STUDY SELECTION Approved applications based on non-RCTs were included; RCTs, studies with
insufficient information, duplicates, and safety data were excluded.
DATA EXTRACTIONAND SYNTHESIS Data were extracted by 2 independent investigators. A
statistical association of themagnitude of estimated effect (expressed as an odds ratio) with FDA
requests for RCTs was assessed. The data were also meta-analyzed to evaluate the differences in
odds ratios between applications that required further testing and those that did not. The results are
reported according to Preferred Reporting Items for Systematic Reviews andMeta-analyses
(PRISMA) guidelines.
MAINOUTCOMESANDMEASURES Disease, laboratory, and patient-related outcomes, including
disease response or patient survival, were considered.
RESULTS Among 677 drug andmedical device applications, 68 (10.0%) were approved by the FDA
based on non-RCTs. Estimates of effects were larger when no further RCTs were required (mean
natural logarithm of the odds ratios, 2.18 vs 1.12; odds ratios, 8.85 vs 3.06; P = .03). Themeta-analysis
results confirmed these findings: estimated effects were approximately 2.5-fold higher for
treatments or devices that were approved based on non-RCTs than for treatments or devices for
which further testing in RCTs was required (6.30 [95% CI, 4.38-9.06] vs 2.46 [95% CI, 1.70-3.56];
P < .001). Overall, 9 of 677 total applications (1.3%) that were approved on the basis of non-RCTs had
relative risks of 10 or greater and 12 (1.7%) had relative risks of 5 or greater. No clear threshold above
which the FDA approved interventions based on the magnitude of estimated effect alone was
detected.
(continued)
Key Points
Question Are US Food and Drug
Administration (FDA) decisions to
approve new therapies based on
nonrandomized clinical trials (non-RCTs)
associated with the sizes of
treatment effects?
Findings In this systematic review and
meta-analysis, the magnitude of
treatment effects was approximately
2.5-fold higher among treatments that
were approved based on non-RCTs than
among treatments that required further
testing in RCTs, but only approximately
1% to 2% of the drugs approved by the
FDA based on non-RCTs displayed
so-called dramatic effects. No clear
threshold of magnitude of treatment
effect above which the FDAwould not
request further RCTs was found.
Meaning Based on this study’s findings,
the size of therapeutic effects was
important to FDA approval of
treatments based on non-RCTs.
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Abstract (continued)
CONCLUSIONS ANDRELEVANCE In this study, estimatedmagnitudes of effect were larger among
studies for which the FDA did not require RCTs comparedwith studies for which it did. Therewas no
clear threshold of treatment effect above which no RCTs were requested.
JAMA Network Open. 2019;2(9):e1911111. doi:10.1001/jamanetworkopen.2019.11111
Introduction
A well-designed randomized clinical trial (RCT) is widely considered the most reliable approach for
evaluating the efficacy of clinical interventions or assessing the probable benefit of a medical device.
However, RCTs often face practical limitations, such as difficulties in accruing patients, or other
logistical or feasibility issues. As a result, alternative methods for the evaluation of treatments are
increasingly considered, such as the assessment of a health interventions’ effects in nonrandomized,
observational studies.1 Although such evaluations often provide results similar to those seen in
RCTs,2,3 exceptions are not uncommon.4 Themain concern about non-RCTs is that it is currently
challenging to predict with confidence when the results of RCTs will be concordant with those of
observational studies. The consequences of such a discordance can sometimes be disastrous.5,6
It is essential to explore when observational studies are considered sufficiently credible.
Regulatory agencies, such as the US Food and Drug Administration (FDA) and the European
Medicines Agency (EMA), have accepted that large treatment effects can sometimes obviate the
need for RCTs. They have accepted that non-RCTs can be considered reliable sources of evidence, ie,
produce results with a low risk of bias, when they generate sufficiently large or dramatic effects that
are thought to rule out the combined effects of bias and random errors.7 Therefore, an approach for
evaluatingwhen findings in observational studies can be considered credible because of sufficiently
dramatic treatment effects is to analyze the approval decisions of the drug licensing authorities.
Based on theoretical and simulation studies, several definitions have been proposed to categorize
dramatic effects as those treatments displaying relative risks (RRs) of 5 or greater8 or 10 or greater9
or odds ratios (ORs) of 12 or greater.10
Using these definitions, we showed that the EMA approved 7% of treatments based on
non-RCTs; between 2% and 4% of these approvals displayed dramatic effects.10 Like the EMA
Priority Medicines and Adaptive Pathways programs, the FDA has a program called the Breakthrough
Therapy designation (BTD), designed to support the approval of drugs demonstrating substantial (ie,
dramatic) improvement over existing therapies and whichmay not require further testing in RCTs.7
In this study, we evaluated the association of the magnitude of treatment effects with FDA
approval based on non-RCTs of drugs within the BTD program andmedical devices within the
Humanitarian Device Exemption (HDE) program. Because the FDA has rarely required devices be
tested in RCTs, it appeared to have implicitly judged that further testing of devices in RCTs may be
unnecessary. However, the FDA has also acknowledged the importance of magnitude of effect in
evaluating devices in the context of the Breakthrough Devices Program.11
We compared themagnitudes of effect of the interventions that were approved without a
request for further randomized evidence vs interventions for which such a request was made. We
hypothesized that the magnitude of treatment effect would be larger among studies for which the
FDA had not requested further RCTs. We also investigated the existence of a possible threshold of
treatment effect, beyond which further testing in RCTs would seem unnecessary.
JAMANetworkOpen | Statistics andResearchMethods Drug and Device Approvals Based on Nonrandomized Clinical Trials
JAMA Network Open. 2019;2(9):e1911111. doi:10.1001/jamanetworkopen.2019.11111 (Reprinted) September 11, 2019 2/11
Downloaded From: https://jamanetwork.com/ by a BOND UNIVERSITY User  on 09/19/2019
Methods
Study Selection
Wedownloaded 606 drug applications in January 2017 (with updated downloads in August 2018) for
treatments within the BTD program from its inception in January 2012 from thewebsites of the FDA
Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research. In August
2017, we downloaded similar data referring to 71 medical devices from the inception of the HDE
program in June 1996. We included consecutive nonrandomized studies from FDA databases (BTD
drugs and HDE devices). We excluded RCTs, studies with nonextractable data, and studies for which
the applicationswere denied. Figure 1 shows the flow diagrams depicting the inclusion and exclusion
process. Because this analysis is based on publicly available data with no patient information
disclosed, institutional review board approval was not needed. This study followed Preferred
Reporting Items for Systematic Reviews andMeta-analyses (PRISMA) reporting guideline.
Data Extraction
Data were extracted independently by 2 of us (M.R. and F.A.K.), using a standardized data extraction
form. Additionally, 25% of the data was randomly verified by 1 of us (M.R.). Nomajor disagreement
was detected. The following data were extracted: study design, primary outcome, disease
characteristics, interventions, and comparators. All outcomes were dichotomous except for 4
interventions. We recorded any FDAmention of whether further RCTs should be desirable, required,
or neither.
Selection of Comparators
Comparator data were extracted from FDA documents. They included control data reported in the
literature associated with no active or standard treatment. When explicit details for the comparators
Figure 1. FlowDiagram of Breakthrough Therapy Designation (BTD) Drug andHumanitarian Device Exemption
Medical Device Applications
606 BTD applications
500 From CDER
106 From CBER
382 Applications denied
309 From CDER
73 From CBER
224 Applications granted
191 From CDER
33 From CBER
126 Applications pending
98 From CDER
28 From CBER
98 Applications approved
93 From CDER
5 From CBER
36 Applications included in analysis
34 From CDER
2 From CBER
62 Applications excluded
58 Approved based on RCT
1 Without extractable data
3 Duplicates
Flow of BTD drug application dataA
32 Medical devices included
in analysis
71 Medical device applications
identified
Flow of medical device application dataB
39 Excluded
10 Had RCT available
1 Superseded by 510(k)
2 Superseded by PMA
6 Were prognostic or
diagnostic tools
2 Were case series
2 Had safety data only
5 Did not have enough data
for extraction
5 Withdrawn with no
documents
6 Had no documentation
available
A, Applications for 606 BTD drugs were downloaded
from the US Food and Drug Administration websites.
B, Applications for 71 devices were downloaded from
the US Food and Drug Administration website.
Consecutive nonrandomized studies from the US Food
and Drug Administration databases were included for
BTD drugs and devices. Exclusions referred to
applications for which randomized clinical trials (RCTs)
were used, case series, denied applications, or studies
with nonextractable data. CBER indicates Center for
Biologics Evaluation and Research; CDER, Center for
Drug Evaluation and Research; and PMA, premarket
approval.
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(ie, events of interest over the number of participants in experimental and control groups) were not
provided, we searched the literature and attempted tomatch experimental with control arms using a
patients-intervention-comparator-outcome framework.12
Estimation of theMagnitude of Effect
Themagnitude of effect was based on the following primary outcomes: overall response rate, overall
survival, objective response rate, and remission rate. For devices, other primary outcomes, such as
clinical improvement and reoperation rate, were also used. We used ORs and/or natural logarithm of
OR (ln[ORs]) as the main metric of magnitude of effect; however, we also presented RRs because
most definitions of dramatic effects were based on RRs. When a very high or very low number of
successes are observed in the control group, RRs cannot have large values, while ORs can range from
0 to infinity. To enable pooling of data from the 4 studieswith dichotomous outcomeswith the other
studies, we computed the standardizedmean differences and converted them to dichotomous
outcomes, as recommended in Cochrane Handbook for Systematic Reviews of Interventions.13
Statistical Analysis
We compared treatment effects of drugs and devices for which the FDA required further testing in
RCTs vs those for which it did not. Our hypothesis was that the magnitude of estimated effect as
expressed as an OR or ln(OR) would be statistically higher in the trials for which the FDA required no
further randomized testing.
We checked the normality of the response variable and then used t tests or the Kruskal-Wallis
test, respectively, to assess for ln(ORs) between the subgroups for which further RCTs would be
required and not required. Related box plots were produced. Furthermore, to compare the average
magnitude of effect between the 2 groups, we meta-analyzed the data and presented forest plots.
We used random-effects modeling to summarize data. A test for subgroup differences was also used.
We applied the above analysis to the drug data, then to the drug and device data combined.
Because the FDA did not express a desire for further RCTs within the device database, we could not
compare the magnitude of effect between the subgroups separately for the device group. Instead,
we computed ORs for the entire group as not requiring further RCTs.
To explore whether FDA decisions had reflected dramatic effects, we defined dramatic effect as
a magnitude of effects with an RR of 5 or greater8 or of 10 or greater.9 We assessed the frequencies
at which drugs or devices were authorized without requesting further RCTs under each definition.
Insufficient datawere available to test whether anORwas 12 or greater, whichwe had identified as an
empirical value for dramatic effects in the EMA study.10
Statistical analyses were conducted in R version 3.4.1 (R Project for Statistical Computing) and
SPSS version 25 (IBM). No prespecified level of statistical significance was set, and all tests were
2-tailed.
Results
Study Selection andData Sources
We examined 606 applications for drugs with BTD as well as 71 applications for medical devices. Our
final sample consisted of 68 interventions (36 BTD drugs, accounting for 6%of all drug applications,
and 32 devices, accounting for 45%of all device applications) (Figure 1).Within the sample, 17 studies
(25%) required further testing via RCTs and 51 (75%) did not. eTable 1 and eTable 2 in the Supplement
show the characteristics of the included studies.
BreakthroughDrug Studies
Overall, 36 drugs authorized by FDAwere based on non-RCTs. All studies used dichotomous data.
Data from prospective studies were used in 34 cases (94%); in the remaining 2 cases, 1 analysis (3%)
was based on retrospective studies and 1 (3%) combined evaluation from prospective and
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retrospective data (Table 1). Most approvals (32 of 36 [89%]) were based on data from single arms.
Comparators were extracted from the main FDA approval documents or were based on historical
controls cited in FDA documents (Table 2). Explicit numbers for both numerator and denominator for
control arms were only available for 10 studies (28%). Of the 36 comparators, 31 (86%) were active
treatments; of those, 14 (45%) included reference to standard treatments. Five studies (14%) were
based on no active treatment (ie, natural history of the disease) (Table 2). Overall response rate was
Table 1. Design andOutcomes of 68 Studies
Design and Outcome
No. (%)
Drugs (n = 36) Devices (n = 32)
Study designs
Prospective 34 (94) 25 (78)
Retrospective 1 (3) 6 (19)
Prospective and retrospective 1 (3) 1 (3)
Single-arm study 32 (89) 30 (94)
Comparator treatments
Active 31 (86) 18 (56)
No active 5 (14) 14 (44)
Outcomes
Overall response rate 24 (67) …
Survival 2 (6) 12 (38)
Objective response rate 5 (14) 1 (3)
Remission 1 (3) 1 (3)
Reoperation NA 1 (3)
Perforation closed NA 1 (3)
Aneurysm NA 3 (9)
Systolic blood pressure NA 1 (3)
Fecal incontinence episodes per
week
NA 1 (3)
Mean prosthetic use score NA 1 (3)
Yale-Brown Obsessive Compulsive
Scale score
NA 1 (3)
Other outcomes 4 (11) 9 (28)
Abbreviation: ellipses, not available; NA, not applicable.
Table 2. Control Arms in 68Drug and Device Studies
Control Arm No. (%)
Breakthrough Drug Studies (n = 36)
Explicitly mentioned in FDA document 10 (28)
Data found in the published manuscript or current
guidelines
16 (44)
Mentioned in FDA document but no explicit
denominator, ie, referred to historical control or
efficacy threshold
5 (14)
Found using literature search 5 (14)
Medical Device Studies (n = 32)
Data explicitly mentioned in FDA document 14 (44)
Natural history data 2 (6)
Mentioned in FDA document but denominator was not
explicitly given
4 (13)
Found in references cited by the FDA 3 (9)
Found using literature search 2 (6)
Found in the published manuscript for the device 7 (22)
Abbreviation: FDA, US Food and Drug Administration.
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the most commonly used outcome (Table 1). Themedian number of patients in the experimental
arms was 106 (range, 8-411).
Of 36 FDA drug approvals, the following 5 drugs were also in the EMA database: ofatumumab,
blinatumomab, idarucizumab, asfotase alfa, and ceritinib. However, asfotase alfa is counted once in
the EMA database and split into 2 indications in the FDA database. Therefore, 30 drugs were unique
to the FDA data, and 46were unique to EMA data.
Studies onDevices
A dichotomous outcomewas used in 28 of 32 device studies (88%), and a continuous outcome in 4
(13%). Data from prospective studies were used in 25 approvals (78%), from retrospective studies in
6 (19%), and from retrospective and prospective data in 1 (3%) (Table 1). Most studies (30 of 32
[94%]) were single-arm trials. Comparators were often based on baseline values, historical data, or
cited in approval documents. Explicit numbers for control arms were available for 14 devices (44%)
(Table 2). Overall, 18 comparators (56%) were active treatments, and 14 (44%) were no active
treatments (ie, natural history or comparison with baseline values). Twelve outcomes (38%)
consisted of survival data at different periods (Table 1). The 4 continuous outcomes included systolic
blood pressure, weekly fecal incontinence episodes, mean prosthetic use score, and Yale-Brown
Obsessive Compulsive Scale score at 12 months. Themedian number of patients in experimental arm
was 31 (range, 12-597), excluding the 4 studies using continuous variables.
Magnitude of Effects According to Requirement for Further RCTs
The eFigure in the Supplement displays box plots of the estimatedmagnitude of effects based on raw
data. The distribution of magnitude of the estimated effects ranged from an OR of 0.66 to 2566.00
in the drug group and from anOR of 0.32 to 2807.00 for the combined group. Based on the raw data,
themagnitude of estimated effects was higher in the group that did not require RCTs comparedwith
the group that did require RCTs (drug-only group: mean ln[OR], 2.23 [OR, 9.34; SD, 1.83] vs mean
ln[OR], 1.12 [OR, 3.06; SD, 1.32]; P = .02; combined group: mean ln[OR], 2.18 [OR, 8.82; SD, 1.98] vs
mean ln[OR], 1.12 [OR, 3.06; SD, 1.32]; P = .03).
Because the FDA did not express a desire to confirm the observed effects in additional RCTs for
the devices, a separate analysis according to the request for future RCTs of deviceswas not possible.
However, themagnitude of effect observed for all devices had amean (SD) ln(OR) of 2.14 (2.09) with
a mean (SD) OR of 8.49 (8.10), which was similar to the treatment effects noted for the drugs for
which no further testing in RCTs was required.
Themeta-analysis also yielded a statistically larger magnitude of estimated effects associated
with the group that did not require RCTs than for the group that did require further RCTs (BTD drugs:
OR, 6.79 [95% CI, 3.90-11.80] vs OR, 2.46 [95%CI, 1.70-3.56]; P = .003; combined group: OR, 6.30
[95% CI, 4.38-9.06] vs OR, 2.46 [95% CI, 1.70-3.56]; P < .001) (Figure 2). The meta-analytic
estimate of ORs for the devices based on all data was an OR of 6.09 (95% CI, 3.70-10.03).
Assessment of Dramatic Effect Threshold
Regardless of which criterion for dramatic effect was used (Figure 3), we were unable to identify any
clear threshold beyond which the FDAwould not require additional randomized evidence. Overall,
12 studies (26%) for which the FDA did not request a subsequent RCT noted RRs of 5 or greater vs 2
studies (12%) for which it did (P = .27). We observed RRs of 10 or greater in 9 studies (19%) for which
the FDA did not request a subsequent RCTs vs 1 (6%) for which it did (P = .38). Overall, 9 of 677 total
applications (1.3%) that were approved on the basis of non-RCTs had RRs of 10 or greater and 12
(1.7%) had RRs of 5 or greater.
We did not perform detailed qualitative analyses of FDA reports. However, our reading of FDA
documents indicated that 2 other factors may be associated with the decision to approve drugs or
devices based on non-RCTs: first, rare diseases, for which there are logistical and feasibility issues
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JAMA Network Open. 2019;2(9):e1911111. doi:10.1001/jamanetworkopen.2019.11111 (Reprinted) September 11, 2019 6/11
Downloaded From: https://jamanetwork.com/ by a BOND UNIVERSITY User  on 09/19/2019
related to conducting RCTs, and, second, the belief that outcomes in control arms are so well known
that RCTs would not be necessary.
Discussion
A system of RCTs is widely considered themost reliable vehicle for advances in therapeutics that
result in the development of slightly more than 50% of new treatments that are superior to standard
treatments.14 Paradoxically, it is this very randomization that is increasingly seen as a barrier tomore
efficient drug development.15 Therefore, increasing calls for using observational, real-world data in
drug development and the practice of medicine are being made.16 However, even though previous
studies comparing the reliability of the use of observational studies with RCTs for drug development
and use found that the results of observational researchwere often similar to those of experimental
studies, they also concluded that the results can frequently differ to the extent that it is impossible to
predict with confidence the amount and direction of bias in observational research.2 The only other
Figure 2. Forest Plots Summarizing Estimated Effects
Favors Control
Treatments
Favors Experimental
Treatment
Odds Ratio (95% CI)
1010.1
Category
RCT required
RCT not required
0.90 (0.19)
1.92 (0.28)
Estimated
Effect (SE)
17
19
No. of
Studies
OR
(95% CI)
6.79 (3.90-11.80)
2.46 (1.70-3.56)
Weight,
%
51.6
48.4
Estimated effects of drugs aloneA
Favors Control
Treatments
Favors Experimental
Treatment
Odds Ratio (95% CI)
1010.1
Category
RCT required
RCT not required
0.90 (0.19)
1.84 (0.19)
Estimated
Effect (SE)
17
51
No. of
Studies
OR
(95% CI)
6.30 (4.38-9.06)
2.46 (1.70-3.56)
Weight,
%
30.3
69.7
Estimated effects of BTD drugs and medical devicesB
Estimated effect and SE refer to the natural logarithm
of the odds ratio (OR) and the SE of the natural
logarithm of the OR, respectively. Box sizes indicate
effect size, number of participants, and size of SE; RCT
indicates randomized clinical trial.
Figure 3. Request for Randomized Clinical Trials (RCTs) According to 2 Criteria of Dramatic Effects
15 Studies with RR less than 5
2 Studies with RR of 5 or more
17 Studies for which FDA requested an RCT
35 Studies with RR less than 5
12 Studies with RR of 5 or more
47 Studies for which FDA did not request an RCT
64 Studies
Studies with RRs less or greater than 5A
16 Studies with RR less than 10
1 Studies with RR of 10 or more
17 Studies for which FDA requested an RCT
38 Studies with RR less than 10
9 Studies with RR of 10 or more
47 Studies for which FDA did not request an RCT
64 Studies
Studies with RRs less or greater than 10B
A, US Food andDrug Administration (FDA) requests for
RCTs by studies, stratified by definition of dramatic
effect as a risk ratio (RR) of 5 or greater.8 B, US Food
and Drug Administration requests for RCTs, stratified
by definition of dramatic effects as RR of 10 or
greater.9 The denominator is 64 because 4 studies had
continuous data as their primary outcome, thereby
preventing the computation of RRs.
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way to replace randomization and reliably assess if new treatments are better than old ones is to
develop drugs displaying very large (ie, dramatic) effects.9 Such dramatic effects are believed to be
reliable because the sheer magnitude of the treatment differences is deemed sufficient to override
the combined effects of allocation bias and random error (for which randomization so effectively
controls).9 As a result, drug development has been increasingly characterized by searching for
treatments with dramatic effects. It is thought that the application of rational drug design and the
exploitation of omics-based technologies to develop precisionmedicine and targeted therapies
could replace the RCT system; hence, testing in observational studies (ie, non-RCTs) could suffice.
But how large is large, and when should effects be considered sufficiently dramatic that further
testing in RCTs is not needed?What is the probability of developing treatments that will have
dramatic effects when tested in patients? Having such empirical benchmarks may arguably speed up
the drug discovery process.
One way to answer these questions is to evaluate how often and with what size treatment
effects regulatory agencies such as the FDA approve drugs for clinical use without requiring testing
in RCTs. When enrollment in RCTs is difficult owing to practical limitations, a strong estimated effect
may be sufficient to convince regulators that such testing is unnecessary.17 In fact, the FDA and EMA
have introduced regulatory mechanisms to support the approval of drugs demonstrating substantial
improvement over existing therapies based on testing in non-RCTs.7 However, empirical evidence
concerning themagnitude of estimated treatment effects sufficient to approve novel medical
treatments, especially if the proposed intervention is based on observational evidence, is limited.
In our previous work, we found that the EMA approved 7% of drugs based on data from
nonrandomized studies alone. Of those, between 2% and 4% of EMA approvals based on
nonrandomized data exhibited so-called dramatic effects; we also found that larger effect sizes in
nonrandomized studies were associated with higher rates of EMA licensing approval.10
In the EMA study, estimates of dramatic effects based on observational data were seen in 32%
of interventions using the criteria of an RR of 10 or greater and 40%of interventions using the criteria
of an RR of 5 or greater.8,9 In the current study, the FDA approved 10.0% (68 of 677) of drugs or
devices based on observational studies. The rate was very similar to the EMA rate when drugs were
considered, while it was much higher for devices in FDA studies. Depending on the definition,
dramatic effects were observed in between 1.3% (9 of 677) and 1.7% (12 of 677) of FDA approvals.
This should be contrasted with the 50% success rate if the drug is brought forward to evaluation
in RCTs.14
In our EMA study,10 the average OR beyond which the agency would not require further testing
in RCTs was 12; however, in the FDA data, the respective ORwas substantially smaller (6.3). The
current study confirms the observations wemade evaluating EMA approvals,10 indicating that when
largermagnitudes of effects are seen in non-RCTs, there is less desire from the regulatory agency to
require subsequent confirmatory RCTs. However, as with our earlier study,10 we found no clear
evidence of a threshold above which FDAwould approve drugs or devices based solely on the
magnitude of estimated effects. This implies that other factors may play significant roles in FDA
decisions regarding approvals based on non-RCT studies.
Limitations
Our study has several limitations. Although it was based on all studies of drugs approved using
non-RCTs within the FDA BTD and device programs, our sample size remained small.
Second, the availability of data on comparators was inadequate. As the evaluation of the effects
of treatments always entails a comparison, this is very concerning; as in the case of our EMA
analysis,10 the available data did not frequently have clear descriptions of numerators and
denominators in experimental and control arms. As a result, some of our treatment effect estimates
were necessarily approximations. In fact, explicit numbers for control arms were available in only
about one-third of instances. A number of comparisons of primary outcomes relied on historical data,
with few explanations of the rationale of the chosen comparators given. If reliable data on controls
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are not available, how did the FDAmake a judgement that is transparent to the public? In our attempt
to associate magnitudes of effects with FDA decisions, we also noticed that the FDA assumed very
low event rates for favorable outcomes in the control arm based on few observations, resulting in
some estimates of improbably large magnitudes of effects. Thus, as with the EMA cohort, we judged
that the quality of the underlying evidence used tomake approval decisions was very low and
unaccompanied by transparent justifications. Because of this, we deemed it unnecessary to assess
the quality of studies on other dimensions recommended by Downs and Black,18 which we used in
our EMA study. However, even under these best case scenarios, the averagemagnitude of estimated
effects observed formost of the breakthrough interventionswas relativelymodest. This should give
us a pause regarding the current excitement surrounding the development of drugs using a precision
medicine approach19 apparently aimed to detect treatments with very large effects. Similar results
observed in the analysis of the EMA and FDA databases appear to reinforce a more cautious and
realistic approach to drug development and drug licensing.
Although larger estimates of effects were noticed in the group that required RCTs than in the
group that did not, we did not detect any threshold dramatic effect. In the future, as more studies
become available, identifying a cutoff point may be feasible and useful. Indeed, discovering such a
threshold may serve as an important benchmark20 for the development of drugs and devices based
on observational studies.We believe that discovering threshold effect size and defining how large a
treatment effect should be to obviate RCTs are currently among the most pressing clinical research
questions. The answers could be informative for clinical trialists (to decide if they should pursue RCTs
vs non-RCTs), practitioners (to decide if the treatment effect of a particular drug is unaffected by
bias), and drug developers (to provide themwith benchmarks in terms of likelihood of developing a
treatment with dramatic effects).
Our findings of no clear evidence of a dramatic effect threshold raised the issue of the
importance of other factors that may have influenced the FDA approval decisions, such as
treatments for rare diseases or current treatments that are thought to be so well known that
comparison with novel treatments may appear unnecessary. Better understanding of FDA decisions
might be gleaned by further in-depth, formal qualitative analyses.
Conclusions
In this study, we explored the association of magnitude of estimated effects with FDA requests for
further testing in RCTs. We concluded that the FDA has not requested subsequent RCTs when a
treatment has displayed a larger magnitude of estimated treatment effects. However, the quality of
data on which the FDA and EMA5 presumptively make these estimates and eventually decisions for
approval is very low. As inferences about treatment effects always rely on comparisons (direct or
counterfactual), greater transparency about the basis for choosing (historical) comparators is needed
to instill confidence that decisions about drug and device approval based on observational data are
appropriate.
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